In vivo and in vitro EZH2 inhibition in bladder cancer significantly upregulates CIITA levels and tsMHC-II and the efficacy of therapy in vivo is wholly dependent on adaptive immunity. This evidence concerns the gene CIITA and urinary bladder cancer.